syringaresinol has been researched along with Prostatic Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andavar, S; Jayaraman, S; Kotha, S; Muthu, S; Selvaraj, D; Siddamsetty, RS | 1 |
1 other study(ies) available for syringaresinol and Prostatic Neoplasms
| Article | Year |
|---|---|
Syringaresinol as a novel androgen receptor antagonist against wild and mutant androgen receptors for the treatment of castration-resistant prostate cancer: molecular docking,
Topics: Androgen Receptor Antagonists; Furans; Humans; Lignans; Male; Molecular Docking Simulation; Molecular Dynamics Simulation; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2021 |